DE637241T1 - Synergistische kombination einer substanz mit hemmwirkung auf die magensäuresekretion und eines säureinstabilen antibiotikums. - Google Patents

Synergistische kombination einer substanz mit hemmwirkung auf die magensäuresekretion und eines säureinstabilen antibiotikums.

Info

Publication number
DE637241T1
DE637241T1 DE0637241T DE93912028T DE637241T1 DE 637241 T1 DE637241 T1 DE 637241T1 DE 0637241 T DE0637241 T DE 0637241T DE 93912028 T DE93912028 T DE 93912028T DE 637241 T1 DE637241 T1 DE 637241T1
Authority
DE
Germany
Prior art keywords
combination according
acid
substance
helicobacter pylori
antibacterial compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE0637241T
Other languages
German (de)
English (en)
Inventor
Arne Torsten S-619 00 Trosa Eek
Sven Erik S-151 33 Soedertaelje Sjoestrand
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
Astra AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26661401&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE637241(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from SE9201297A external-priority patent/SE9201297D0/xx
Priority claimed from SE9300029A external-priority patent/SE9300029D0/xx
Application filed by Astra AB filed Critical Astra AB
Publication of DE637241T1 publication Critical patent/DE637241T1/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/04—Surgical instruments, devices or methods for suturing wounds; Holders or packages for needles or suture materials
    • A61B17/0469—Suturing instruments for use in minimally invasive surgery, e.g. endoscopic surgery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/04—Surgical instruments, devices or methods for suturing wounds; Holders or packages for needles or suture materials
    • A61B17/06—Needles ; Sutures; Needle-suture combinations; Holders or packages for needles or suture materials
    • A61B17/06066—Needles, e.g. needle tip configurations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/34—Trocars; Puncturing needles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/30—Joints
    • A61F2002/30001—Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
    • A61F2002/30003—Material related properties of the prosthesis or of a coating on the prosthesis
    • A61F2002/3006—Properties of materials and coating materials
    • A61F2002/30092—Properties of materials and coating materials using shape memory or superelastic materials, e.g. nitinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2210/0014—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof using shape memory or superelastic materials, e.g. nitinol
    • A61F2210/0023—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof using shape memory or superelastic materials, e.g. nitinol operated at different temperatures whilst inside or touching the human body, heated or cooled by external energy source or cold supply
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2210/0014—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof using shape memory or superelastic materials, e.g. nitinol
    • A61F2210/0023—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof using shape memory or superelastic materials, e.g. nitinol operated at different temperatures whilst inside or touching the human body, heated or cooled by external energy source or cold supply
    • A61F2210/0047—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof using shape memory or superelastic materials, e.g. nitinol operated at different temperatures whilst inside or touching the human body, heated or cooled by external energy source or cold supply heated by light

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Surgery (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medical Informatics (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE0637241T 1992-04-24 1993-04-20 Synergistische kombination einer substanz mit hemmwirkung auf die magensäuresekretion und eines säureinstabilen antibiotikums. Pending DE637241T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9201297A SE9201297D0 (sv) 1992-04-24 1992-04-24 Synergistic combination
SE9300029A SE9300029D0 (sv) 1993-01-08 1993-01-08 Synergistic combination ii
PCT/SE1993/000327 WO1993021920A1 (en) 1992-04-24 1993-04-20 Synergistic combination of a substance with gastric acid secretion inhibiting effect and an acid degradable antibiotic

Publications (1)

Publication Number Publication Date
DE637241T1 true DE637241T1 (de) 1997-09-11

Family

ID=26661401

Family Applications (2)

Application Number Title Priority Date Filing Date
DE0637241T Pending DE637241T1 (de) 1992-04-24 1993-04-20 Synergistische kombination einer substanz mit hemmwirkung auf die magensäuresekretion und eines säureinstabilen antibiotikums.
DE69328967T Revoked DE69328967T2 (de) 1992-04-24 1993-04-20 Synergistische kombination einer substanz mit hemmwirkung auf die magensäuresekretion und eines säureinstabilen antibiotikums

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69328967T Revoked DE69328967T2 (de) 1992-04-24 1993-04-20 Synergistische kombination einer substanz mit hemmwirkung auf die magensäuresekretion und eines säureinstabilen antibiotikums

Country Status (38)

Country Link
US (3) US5599794A (enExample)
EP (2) EP0956857A3 (enExample)
JP (1) JPH07505901A (enExample)
KR (1) KR100340165B1 (enExample)
CN (1) CN1041798C (enExample)
AP (1) AP466A (enExample)
AT (1) ATE194286T1 (enExample)
AU (1) AU669903B2 (enExample)
CA (1) CA2133762C (enExample)
CZ (1) CZ291201B6 (enExample)
DE (2) DE637241T1 (enExample)
DK (1) DK0637241T3 (enExample)
DZ (1) DZ1683A1 (enExample)
EE (1) EE03149B1 (enExample)
ES (1) ES2100135T3 (enExample)
FI (1) FI944953A7 (enExample)
GR (2) GR970300011T1 (enExample)
HR (1) HRP930755B1 (enExample)
HU (1) HUT71225A (enExample)
IL (1) IL105155A (enExample)
IS (1) IS3990A (enExample)
LV (1) LV12625B (enExample)
MA (1) MA22878A1 (enExample)
MY (1) MY121189A (enExample)
NO (1) NO314288B1 (enExample)
NZ (1) NZ252759A (enExample)
PL (1) PL173485B1 (enExample)
PT (1) PT637241E (enExample)
RO (1) RO115780B1 (enExample)
RU (1) RU2143899C1 (enExample)
SG (1) SG52485A1 (enExample)
SI (1) SI9300219B (enExample)
SK (1) SK282420B6 (enExample)
TN (1) TNSN93040A1 (enExample)
TW (1) TW276996B (enExample)
UA (1) UA43830C2 (enExample)
WO (1) WO1993021920A1 (enExample)
YU (1) YU49091B (enExample)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW420610B (en) * 1994-04-07 2001-02-01 Pfizer A pharmaceutical composition for treating a H. pylori infection or gastric or duodenal ulcers
SE9500422D0 (sv) * 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
US6132768A (en) * 1995-07-05 2000-10-17 Byk Gulden Lomberg Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for reversible proton pump inhibitors
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
CN1061232C (zh) * 1996-04-12 2001-01-31 马理国 一种治疗胃炎、溃疡的药物组合物
SI9700186B (sl) 1997-07-14 2006-10-31 Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin
ES2232015T3 (es) * 1997-07-25 2005-05-16 Altana Pharma Ag Inhibidor de las bombas de protones en combinacion terapeutica con sustancias antibacterianas.
US6174548B1 (en) 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6096340A (en) * 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6733778B1 (en) * 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6117868A (en) * 1998-09-16 2000-09-12 Ed. Geistlich Sohne Ag Fur Chemische Industrie Treatment of gastrointestinal ulcers or gastritis caused by microbial infection
WO2000050037A1 (en) * 1999-02-26 2000-08-31 Nitromed, Inc. Nitrosated and nitrosylated proton pump inhibitors, compositions and methods of use
US6852739B1 (en) * 1999-02-26 2005-02-08 Nitromed Inc. Methods using proton pump inhibitors and nitric oxide donors
US6245913B1 (en) 1999-06-30 2001-06-12 Wockhardt Europe Limited Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole
US6369087B1 (en) * 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6312723B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Pharmaceutical unit dosage form
US6262086B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Pharmaceutical unit dosage form
US6262085B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6316020B1 (en) * 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
US6326384B1 (en) 1999-08-26 2001-12-04 Robert R. Whittle Dry blend pharmaceutical unit dosage form
US6268385B1 (en) 1999-08-26 2001-07-31 Robert R. Whittle Dry blend pharmaceutical formulations
US6780880B1 (en) 1999-08-26 2004-08-24 Robert R. Whittle FT-Raman spectroscopic measurement
US6312712B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Method of improving bioavailability
US7365047B1 (en) * 1999-09-28 2008-04-29 The Regents Of The University Of California Use of pentagastrin to inhibit gastric acid secretion or as a diuretic
US20020004502A1 (en) * 2000-01-05 2002-01-10 Redmond H. Paul Treatment of inflammatory bowel disease
US6787342B2 (en) 2000-02-16 2004-09-07 Merial Limited Paste formulations
WO2001064224A1 (en) * 2000-02-29 2001-09-07 Teva Pharmaceutical Industries Ltd. Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same
EP1263445A1 (en) * 2000-03-09 2002-12-11 Ian Whitcroft Treatment of inflammatory dermatoses comprising erythromycin or clarythromycin, metronidazole and a gastrointestinal hydrogen pump inhibitor
EP1133987A1 (en) * 2000-03-09 2001-09-19 Ian Whitcroft Treatment of inflammatory dermatoses with combinations of erythromycin or clarythromycin, metronidazole and a hydrogen pump inhibitor
ATE432691T1 (de) * 2000-03-28 2009-06-15 Sandoz Ag Geschmackmaskierte granulierte teilchen
SE0002476D0 (sv) 2000-06-30 2000-06-30 Astrazeneca Ab New compounds
US6544556B1 (en) * 2000-09-11 2003-04-08 Andrx Corporation Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor
WO2002026210A2 (en) * 2000-09-29 2002-04-04 Geneva Pharmaceuticals Inc. Proton pump inhibitor formulation
SE0103695D0 (sv) 2001-11-07 2001-11-07 Thomas Boren A novel non-antibiotic strategy against OGIP infections based on a cereal product
WO2003063927A2 (en) * 2001-11-16 2003-08-07 Eisai Co. Ltd Compositions and methods to treat gastrointestinal disorders
WO2003063840A2 (en) * 2002-01-25 2003-08-07 Santarus, Inc. Transmucosal delivery of proton pump inhibitors
US20030228363A1 (en) * 2002-06-07 2003-12-11 Patel Mahendra R. Stabilized pharmaceutical compositons containing benzimidazole compounds
AU2003254282A1 (en) * 2002-08-01 2004-02-23 Nitromed, Inc. Nitrosated proton pump inhibitors, compositions and methods of use
CA2515130A1 (en) * 2003-02-05 2004-08-26 Teva Pharmaceutical Industries Ltd. Method of stabilizing lansoprazole
TWI367759B (en) * 2003-02-20 2012-07-11 Santarus Inc A novel formulation, omeprazole antacid complex-immediate release, for rapid and sustained suppression of gastric acid
US20040185092A1 (en) * 2003-03-18 2004-09-23 Yih Ming Hsiao Pharmaceutical preparations of omeprazole and/or clarithromycin for oral use
US8993599B2 (en) * 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
AU2004257864A1 (en) * 2003-07-18 2005-01-27 Santarus, Inc. Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders
CA2531564C (en) * 2003-07-18 2016-01-19 Santarus, Inc. Pharmaceutical composition for inhibiting acid secretion
US8906940B2 (en) * 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) * 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20060194748A1 (en) * 2005-02-28 2006-08-31 National University Corporation Nagoya University Methods for treating disorders induced by H. pylori infections and pharmaceutical compositions for the same
WO2007070164A1 (en) * 2005-10-19 2007-06-21 The Curators Of The University Of Missouri Pharmaceutical composition comprising a proton pump inhibitor, a buffering agent and an anti-h. pylori active substance and methods of using same
US20070141151A1 (en) * 2005-12-20 2007-06-21 Silver David I Lansoprazole orally disintegrating tablets
CA2665226C (en) 2006-10-05 2014-05-13 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
US20080103169A1 (en) 2006-10-27 2008-05-01 The Curators Of The University Of Missouri Compositions comprising acid labile proton pump inhibiting agents, at least one other pharmaceutically active agent and methods of using same
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
US10869690B2 (en) * 2017-06-29 2020-12-22 Ethicon Llc Trocar obturator with transverse needle ports
JP2025532389A (ja) 2022-10-04 2025-09-29 ザビリュク，アルセニー 大動脈弁の石灰化の抑制

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85472A (en) * 1987-03-09 1991-06-30 Procter & Gamble Pharmaceutical compositions for treating gastrointestinal disorders
JP2694361B2 (ja) * 1989-02-09 1997-12-24 アストラ アクチエボラグ 抗菌剤
DE69014141T2 (de) * 1989-02-10 1995-05-24 Takeda Chemical Industries Ltd Verwendung von Benzimidazol-Derivaten als antibakterielle Mittel.
GB9018603D0 (en) * 1990-08-24 1990-10-10 Smith Kline French Lab Compositions
WO1992004898A1 (de) * 1990-09-14 1992-04-02 Byk Gulden Lomberg Chemische Fabrik Gmbh Verwendung von pyridylmethylsulfinyl-1h-benzimidazol derivaten zur behandlung durch helicobacter verursachten erkrankungen

Also Published As

Publication number Publication date
FI944953L (fi) 1994-10-21
EP0637241B1 (en) 2000-07-05
AU4273793A (en) 1993-11-29
HK1008296A1 (en) 1999-05-07
DE69328967D1 (de) 2000-08-10
HRP930755B1 (en) 2001-04-30
SK127594A3 (en) 1995-04-12
EP0956857A3 (en) 2003-11-26
GR3034470T3 (en) 2000-12-29
KR100340165B1 (ko) 2002-10-04
UA43830C2 (uk) 2002-01-15
NO314288B1 (no) 2003-03-03
YU49091B (sh) 2003-12-31
DK0637241T3 (da) 2000-09-11
AP9300518A0 (en) 1993-04-30
CN1041798C (zh) 1999-01-27
YU27593A (sh) 1996-10-09
US5599794A (en) 1997-02-04
HU9403069D0 (en) 1994-12-28
DE69328967T2 (de) 2000-12-07
AU669903B2 (en) 1996-06-27
AP466A (en) 1996-03-05
LV12625B (en) 2001-07-20
NO944010D0 (no) 1994-10-21
HUT71225A (en) 1995-11-28
US5629305A (en) 1997-05-13
SI9300219B (en) 2001-12-31
IS3990A (is) 1993-10-25
RO115780B1 (ro) 2000-06-30
WO1993021920A1 (en) 1993-11-11
ES2100135T1 (es) 1997-06-16
CA2133762A1 (en) 1993-11-11
SK282420B6 (sk) 2002-01-07
DZ1683A1 (fr) 2002-02-17
FI944953A0 (fi) 1994-10-21
MA22878A1 (fr) 1993-12-31
SG52485A1 (en) 1998-09-28
CZ259394A3 (en) 1995-08-16
TNSN93040A1 (fr) 1994-03-17
US5633244A (en) 1997-05-27
NO944010L (no) 1994-10-21
MY121189A (en) 2006-01-28
PT637241E (pt) 2000-10-31
ES2100135T3 (es) 2000-11-16
ATE194286T1 (de) 2000-07-15
FI944953A7 (fi) 1994-10-21
NZ252759A (en) 1996-12-20
CN1081614A (zh) 1994-02-09
GR970300011T1 (en) 1997-05-31
IL105155A (en) 1999-05-09
RU2143899C1 (ru) 2000-01-10
CA2133762C (en) 2000-08-01
HRP930755A2 (en) 1994-10-31
EE03149B1 (et) 1999-02-15
EP0637241A1 (en) 1995-02-08
IL105155A0 (en) 1993-07-08
PL173485B1 (pl) 1998-03-31
CZ291201B6 (cs) 2003-01-15
SI9300219A (sl) 1993-12-31
JPH07505901A (ja) 1995-06-29
LV12625A (en) 2001-03-20
TW276996B (enExample) 1996-06-01
EP0956857A2 (en) 1999-11-17

Similar Documents

Publication Publication Date Title
DE69328967T2 (de) Synergistische kombination einer substanz mit hemmwirkung auf die magensäuresekretion und eines säureinstabilen antibiotikums
DE3343200C2 (enExample)
DE3705151C2 (enExample)
DE69211682T2 (de) Mittel gegen zahnbelag bestehend aus nichtantibakteriellem tetracyclin
DE3011182A1 (de) Zur oralen verabreichung geeignete zusammensetzung
DE3601132A1 (de) Verfahren zur behandlung der schleimhaut
DE69725860T2 (de) PLAN ZUR VERABREICHUNG VON H+, K+-ATPase INHIBITOREN
DE2922664A1 (de) Gegen zahnsteinbildung wirksame orale zusammensetzung
ATE141511T1 (de) Verwendung eines bakteriozin antibiotischen agenten zur herstellung eines arzneimittels zur behandlung von magenverstimmungen, die durch helicobacter pylori verursacht werden.
RU99107569A (ru) Фармацевтические композиции, обладающие антимикробной активностью
DE69322075T2 (de) Zusammensetzungen
CH645268A5 (de) Bakteriostatikum und verfahren zu dessen herstellung.
Stindt et al. An overview of Gly-Oxide liquid in control and prevention of dental disease
DE69125940T2 (de) Pharmazeutische zusammensetzungen die 5-difluormethoxy-2-[3,4-dimethoxy-2-pyridyl)methylsulfinyl]-1h-benzimidazol und ein anti-heliobactermittel enthalten zur behandlung von magen-darm krankheiten
DE4017964A1 (de) Medizinalfutter zur systematischen behandlung von ektoparasitaeren und ektobakteriellen erkrankungen von zier- und nutzfischen
DE2700448A1 (de) Heilmittel gegen ulcus cruris
DD273977A5 (de) Verfahren zur herstellung eines stomatologischen praeparates
DE69733169D1 (de) Verwendung von Alpha-1-Adrenorezeptor-Antagonisten zur Herstellung eines Medikaments für die Vorbeugung und die Behandlung von Krebs
DE69104608T2 (de) Pharmazeutische Zubereitungen, Clavulansäure enthaltend, für die Behandlung der Periodontitis.
DE69733037T2 (de) Schutz zur verminderung von zahnbelag
EP0362471B1 (de) Prophylaktikum für Fische
DE69511453D1 (de) Verwendung einer Kombination von Antineoplastonen zur Herstellung eines Arzneimittels zur Behandlung der Neurofibromatose
EP0173950A3 (de) Neuer alpha-Glukosidase Inhibitor, Verfahren zur seiner Herstellung, seine Verwendung und pharmazeutische Präparate
DE3728367C1 (de) Mittel zur Immunisierung des menschlichen Koerpers bei HIV-Infektionen
DE3770551D1 (de) Verfahren zur herstellung eines pulvers mit grosser wundheilungsfaehigkeit aus der rinde des baumes namens "mimosa tenuiflora poir".